# NAD Augmentation in Diabetes Kidney Disease

> **NCT05759468** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 156 (estimated)

## Conditions studied

- Type2diabetes
- Diabetic Kidney Disease

## Interventions

- **DRUG:** Investigational Product - MIB 626
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05759468
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-13
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-03-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759468, "NAD Augmentation in Diabetes Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05759468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*